Predicted protein targets (top 5)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CYP3A4 | P08684 | 1/20 | 0.57 |
| ▸ | SLC7A5 | Q01650 | 1/20 | 0.57 |
| ▸ | NLN | Q9BYT8 | 2/20 | 0.53 |
| ▸ | GHSR | Q92847 | 1/20 | 0.49 |
| ▸ | REN | P00797 | 1/20 | 0.48 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1230293 | 0.90 | CYP3A4 (0.65) | CYP3A4SLC7A5NLN | |
| SCHEMBL24725104 | 0.86 | CYP3A4 (0.53) | CYP3A4SLC7A5GHSRREN | |
| SCHEMBL21828671 | 0.84 | CYP3A4 (0.68) | CYP3A4SLC7A5NLN | |
| SCHEMBL13467352 | 0.82 | CYP3A4 (0.49) | CYP3A4SLC7A5 | |
| SCHEMBL29380221 | 0.82 | CYP3A4 (0.65) | CYP3A4SLC7A5REN | |
| SCHEMBL21828631 | 0.81 | CYP3A4 (0.63) | CYP3A4SLC7A5NLN | |
| SCHEMBL31066556 | 0.81 | CYP3A4 (0.63) | CYP3A4SLC7A5NLN | |
| SCHEMBL23484143 | 0.81 | CYP3A4 (0.56) | CYP3A4SLC7A5NLN | |
| SCHEMBL29727567 | 0.80 | CYP3A4 (0.59) | CYP3A4SLC7A5NLN | |
| SCHEMBL16628203 | 0.80 | SLC15A2 (0.63) | CYP3A4SLC7A5REN |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-10851367-B2 | Tissue-specific genome engineering using CRISPR-Cas9 | PFIZER INC. (US) | 2020-12-01 | — | — | US | disclosed |
| US-20170137801-A1 | TISSUE-SPECIFIC GENOME ENGINEERING USING CRISPR-CAS9 | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA | 2017-05-18 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-10851367-B2 | Tissue-specific genome engineering using CRISPR-Cas9 | ASGR1, LDLR, HAVCR2 | CYP3A4 3252/4885SLC7A5 3548/4885NLN 2054/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.